WellMedr GLP-1 Review (2026): Pricing, Coverage, and Tradeoffs

Item: WellMedr
Author: RangeYourself

WellMedr review. We publish no price for WellMedr: the figures it advertises conflict across its own pages and rest on a basis it does not publish. Microdose-GLP-1 blend plans (tirzepatide combined with NAD+ or B12/MIC in one $199/mo subscription) and flat-priced prescription NAD+ ($99/mo advertised, same price every dose). Independent 2026 review from RangeYourself.

By RangeYourselfLast verified 2026-08-10

Quick take

WellMedr is compounded semaglutide and tirzepatide (injectable and oral), a distinct microdose glp-1 blend line (tirzepatide with nad+/b12 or b12/methionine/inositol), brand ozempic and zepbound listings, plus nad+, trt/enclomiphene, ed and hair-loss lines on one telehealth menu, priced as cash-pay recurring subscription enrolled at purchase; main glp-1 pricing is funnel-gated (shopify catalog exposes $0.00 placeholder variants; no single defensible recurring price, oak/liv body/telos mechanism); the microdose blend line advertises $199/mo on its own page and a '50% off your first month' promo runs on compounded glp-1/gip. Best for: Microdose-GLP-1 blend plans (tirzepatide combined with NAD+ or B12/MIC in one $199/mo subscription) and flat-priced prescription NAD+ ($99/mo advertised, same price every dose). Watch out for: WellMedr's own pages contradict each other on FDA status: a site-wide footer correctly states its compounded medications 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality,' while its FAQ answers 'Are these medications FDA approved? Yes.' and its microdosing page calls them 'FDA-approved compounds' and claims 'ZERO side effects' for most members, claims we do not repeat as fact. No dispensing pharmacy is named, no 503A/503B status is stated, no state list is published, and the main GLP-1 recurring price is only shown inside the intake funnel, confirm the real price, the pharmacy, and your state's eligibility before paying.

Pricing summary

Price surface last checked: 2026-08-10 (we read the provider’s own pricing pages on this date and found no figure we could stand behind)
All-in monthly cost: No single defensible price, see the pricing notes
Semaglutide: Compounded, injectable and oral offered; recurring rate not published on the public site (funnel-gated), confirm at enrollment
Tirzepatide: Compounded, injectable and oral offered; recurring rate not published (funnel-gated). Microdose blend plans containing tirzepatide (with NAD+/B12, or B12/methionine/inositol) are page-priced at $199/mo (verified 2026-08-10), confirm the exact plan at enrollment
Compounded vs brand-name: Both compounded and brand-name
Insurance accepted: No insurance-billing path published (cash-pay); confirm at signup
Consult type: Async questionnaire, per the provider’s published flow
Dose-escalation pricing:
Refund policy:
States served: Not published; WellMedr's own pages say to check whether your state is eligible at signup

→

Choose WellMedr if

You want a microdosed GLP-1 plan sold as a flat $199/mo blend subscription (tirzepatide with NAD+/B12 or B12/MIC) rather than a standard-dose program
You want prescription NAD+ at a flat advertised $99/mo, same price every dose per WellMedr's own page (not the registry's cheapest: Enhance MD's sublingual is $84/mo and bmiMD's injection $89/mo)
You're comfortable confirming the real recurring GLP-1 price inside the intake flow, WellMedr publishes no standing GLP-1 rate on its public site
You've read the FDA-status watchout above and are comfortable with a program whose own pages are inconsistent about it

Skip WellMedr if

Contraindications and clinical notes

. Talk to a clinician about personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, or other conditions before starting any GLP-1 medication.

Verified programs with a published all-in monthly price

WellMedr’s price on file has not passed our current verification cycle, so it is not compared here. The programs below carry a verified all-in monthly price, checked on each provider’s own pricing page and ranked lowest first as of September 3, 2026.

1.Embody
$69/mo (limited-time promo), verified August 21, 2026
See pricing →
2.Strut Health
$99/mo (sublingual/oral starting price), verified August 21, 2026
See pricing →
3.Trimi
$99/mo (annual-plan rate), verified August 21, 2026
See pricing →
4.HealthRX
$99/mo (12-month plan rate), verified August 21, 2026
See pricing →
5.bmiMD
$119/mo (12-month plan rate), verified September 3, 2026
See pricing →

Prices are each provider’s own published all-in monthly figure at the plan term shown, verified on the date listed. RangeYourself may earn a commission from some programs; that can only break an exact tie between verified equals and never changes the price order.

How WellMedr compares

Frequently asked questions

How much does WellMedr cost per month?

WellMedr advertises figures, but we publish none of them as its price: they conflict across its own pages and/or rest on a plan basis it does not disclose, so there is no single defensible ongoing rate to quote. The figures it does advertise, and what each one actually rests on, are set out in full below.

Does WellMedr accept insurance?

WellMedr publishes cash-pay prices and we found no insurance-billing path on its own site. Where a provider's own FAQ leaves the door open, the answer sits inside its intake flow, which we do not enter, so confirm at signup rather than treating this as settled. If you want insurance-billed brand-name GLP-1, see our list of GLP-1 programs that accept insurance.

What states does WellMedr serve?

WellMedr serves Not published; WellMedr's own pages say to check whether your state is eligible at signup.

Is WellMedr compounded or brand-name?

WellMedr offers both compounded GLP-1 and brand-name GLP-1 depending on your eligibility and preference.

What's the catch with WellMedr?

WellMedr's own pages contradict each other on FDA status: a site-wide footer correctly states its compounded medications 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality,' while its FAQ answers 'Are these medications FDA approved? Yes.' and its microdosing page calls them 'FDA-approved compounds' and claims 'ZERO side effects' for most members, claims we do not repeat as fact. No dispensing pharmacy is named, no 503A/503B status is stated, no state list is published, and the main GLP-1 recurring price is only shown inside the intake funnel, confirm the real price, the pharmacy, and your state's eligibility before paying.

Related guides

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

About these products

These are compounded preparations, not FDA-approved for anti-aging or longevity indications, and a prescription from a licensed clinician is required. Compounding pharmacies are not individually reviewed by the FDA for the safety or effectiveness of a specific compounded product. We rank and describe these programs on price and access only, never on efficacy, outcomes, or benefit claims, and we do not repeat a provider’s own marketing claims as independently verified fact.

NAD+: NAD+ is not an FDA-approved drug, and its compounding status is not settled in its favor. In a warning letter to GenoGenix LLC dated January 20, 2026 (WL#718739), the FDA stated that NAD+ is not eligible for compounding by a 503B outsourcing facility. We could not identify a clear 503A pathway for it either: it has no USP monograph and is not a component of an approved drug. A Class I recall of an NAD+ injectable over endotoxin contamination is also on the record. We rank the programs on this page on published price only, and price is not a safety, quality, or eligibility signal here, confirm sourcing, the dispensing pharmacy, and any state restrictions directly with the provider before purchase, and discuss it with a prescribing clinician.

These peptide and longevity products are not identical to, and are never described here as generic or equivalent to, any FDA-approved drug, and unlike compounded GLP-1 medication most of them have no FDA-approved counterpart at all. State availability varies by provider and by product, several programs listed here disclose per-state restrictions; confirm eligibility in your state before purchase. RangeYourself does not provide medical advice and does not guarantee a prescription.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. We publish no price for WellMedr: we read its own pricing pages on 2026-08-10 and found no single figure we could stand behind. Confirm the rate directly with the provider.